2 Research products, page 1 of 1

Publications
Research data
Other research products
2012-2021
Open Access
Article
COVID-19

Sort by

Relevance

arrow_drop_down

Publication . Article . 2020
Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19
Open Access Russian
Authors:
B. K. Romanov;
B. K. Romanov;
doi: 10.30895/1991-2919-2020-10-3-148-151
doi: 10.30895/1991-2919-2020-10-3-148-151
Publisher: OOO “Vashe Tsifrovoe Izdatelstvo”
The review compares individual case safety reports (ICSRs) for hydroxychloroquine, favipiravir, and the lopinavir/ ritonavir combination registered in the VigiBase global database during 6 months in 2019 and the same period in 2020 which coincides with the global “first...
Average popularity
Average popularity In bottom 99%
Popularity: Citation-based measure reflecting the current impact.
View more details
Average influence
Average influence In bottom 99%
Influence: Citation-based measure reflecting the total impact.
View more details
addAdd to ORCID
Please grant OpenAIRE to access and update your ORCID works.
This Research product is the result of merged Research products in OpenAIRE.

You have already added works in your ORCID record related to the merged Research product.
Publication . Article . 2021
Planning Bioequivalence Studies in the Context of the COVID-19 Pandemic
Open Access Russian
Authors:
D. P. Romodanovsky; A. L. Khokhlov; D. V. Goryachev;
D. P. Romodanovsky; A. L. Khokhlov; D. V. Goryachev;
doi: 10.30895/1991-2919-2021-11-1-6-15
doi: 10.30895/1991-2919-2021-11-1-6-15
Publisher: OOO “Vashe Tsifrovoe Izdatelstvo”
The coronavirus (COVID-19) pandemic, which began in 2020, has affected all spheres of life, including clinical trial processes. Health authorities around the world issued recommendations aimed at minimising the risks of virus spreading and ensuring the safety of study p...
Average popularity
Average popularity In bottom 99%
Popularity: Citation-based measure reflecting the current impact.
View more details
Average influence
Average influence In bottom 99%
Influence: Citation-based measure reflecting the total impact.
View more details
addAdd to ORCID
Please grant OpenAIRE to access and update your ORCID works.
This Research product is the result of merged Research products in OpenAIRE.

You have already added works in your ORCID record related to the merged Research product.

Filters

Access (1)

Year range

Document Type (1)

Field of Science [Beta] (5)

Language (1)

Source (1)

Research community (1)

2 Research products, page 1 of 1

Publications
Research data
Other research products
2012-2021
Open Access
Article
COVID-19

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19

Planning Bioequivalence Studies in the Context of the COVID-19 Pandemic

Searching Fields	Terms
Any field arrow_drop_down includes arrow_drop_down

Filters

Access (1)

Year range

Document Type (1)

Field of Science [Beta] (5)

Language (1)

Source (1)

Research community (1)

2 Research products, page 1 of 1

PublicationscloseResearch datacloseOther research productsclose2012-2021close Open Access close Article close COVID-19 close

Safety of Hydroxychloroquine, Favipiravir, and the Combination of Lopinavir and Ritonavir in the Treatment of the “First Wave” of the New Coronavirus Infection COVID-19

Planning Bioequivalence Studies in the Context of the COVID-19 Pandemic

Publications
Research data
Other research products
2012-2021
Open Access
Article
COVID-19